1. [A Case of MSI-High Sigmoid Colon Cancer in Which Long-Term Survival Was Achieved by Pembrolizumab for Recurrent Lesions Resistant to Conventional Chemotherapy].
- Author
-
Tsumuraya H, Kaneta A, Fujita S, Hayashishita S, Mochizuki S, Suzuki H, Takiguchi C, Matsuishi A, Maruyama Y, Kanouda R, Sakuma M, Sakamoto W, Monma T, Saze Z, and Kono K
- Subjects
- Humans, Male, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Sigmoid Neoplasms drug therapy, Sigmoid Neoplasms surgery, Sigmoid Neoplasms pathology
- Abstract
The patient underwent sigmoidectomy with D3 lymph node dissection and partial bladder resection for sigmoid colon cancer(cT4bN1M0, cStage Ⅲa), after preoperative chemotherapy with mFOLFOX plus panitumumab, and FOLFOXIRI plus bevacizumab. Postoperative adjuvant chemotherapy was performed by 8 courses of CAPOX. He relapsed hilar lymph nodes and peritoneal dissemination after 13 months after surgery, he underwent resection of the recurrent lesions. Four months after, he developed recurrence in liver and peritoneum. Although he was treated with FOLFIRI plus ramucirumab or aflibercept, resulted in progression of disease, then he received trifluridine tipiracil hydrochloride plus bevacizumab. At this point, the Japanese health insulance had started to cover pembrolizumab, this therapy was started as the fourth chemotherapy after the diagnosis of high frequency microsatellite instability(MSI), and then tumor markers rapidly declined. He underwent 38 courses of pembrolizumab, the recurrent lesions both liver and peritoneum disappeared. He had stoma closure, peritoneal dissemination disappeared not only intraoperatively but also in histologically from the peritoneal scar. He has received pembrolizumab for 4 years without another recurrence. Here, we report a case of MSI-high sigmoid colon cancer in which long-term survival was achieved by pembrolizumab for recurrent lesions resistant to conventional chemotherapy.
- Published
- 2023